openPR Logo
Press release

Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at Mirati Therapeutics, Inc.

12-01-2021 06:57 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential wrongdoing.

An investigation on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential wrongdoing.

Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. reported that its annual Total Revenue rose from $3.33 million in 2019 to $13.39 million in 2020, and that its Net Loss increased from $212.25 million in 2019 to $357.93 million in 2020.

On November 1, 2021, Mirati Therapeutics, Inc, in an SEC filing, disclosed that certain executives would no longer be serving in their positions. In the filing, the Company stated, “

On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and principal financial officer of Mirati Therapeutics, Inc. (the “Company”) and that Joseph Leveque would cease serving as the Company’s Executive Vice President and Chief Medical Officer, effective as of November 1, 2021.”

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) declined from $195.99 per share on October 25, 2021, to $134.35 per share on November 24, 2021.

Those who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at Mirati Therapeutics, Inc. here

News-ID: 2481995 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Mirati

Investigation announced for Investors in NASDAQ: MRTX shares over possible Viola …
Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mirati Therapeutics, Inc. (NASDAQ: MRTX) concerning whether a series of
KRAS Inhibitors Market to Reveal Strapping Growth in Forthcoming period 2021-202 …
KRAS inhibitors is among the top arising areas of the malignancy therapeutics market which is because of the impressive innovative work pipeline related with the market. The whole market related with KRAS inhibitors, in an extremely brief timeframe has had the option to move the whole malignancy scene, in this manner bringing about the standard consideration of disease treatment with fitting freedoms to the patients and the financial backers. Top Key
KRAS Inhibitors Market Strategists and effective growth for key players Over 202 …
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation may directly influence medical decisions in patients with carcinomas as demonstrated by the recent research. Despite its discovery over three decades ago, it’s remained elusive as a drug target, although several downstream mediators are effectively drugged. KRAS itself is described collectively of the master switches for cancer and is especially associated as a driver for Colorectal Carcinoma (CRC), Non-small Lung cancer (NSCLC),
Myxoid Round Cell Liposarcoma Drug Market 2020 Emerging Players - Adaptimmune, R …
Myxoid Round Cell Liposarcoma Drug Market Research Report By Therapy (Chemotherapy, Radiation Therapy and Others), Drugs (Trabectedin, Mechlorethamine and Others), Route of Administration (Injectable, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026 Few of the major competitors currently working in global myxoid round cell
Histone Deacetylase Inhibitors Market Size, Growth, Share Statistics 2020-2026 | …
Histone Deacetylase Inhibitors Market Research Report 2020 is a valuable supply of insightful information for business strategists with Top Countries Data. Histone Deacetylase Inhibitors Market report provides detailed coverage of Histone Deacetylase Inhibitors industry and main market trends. The Histone Deacetylase Inhibitors Market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Histone Deacetylase Inhibitors by geography. Get Sample Copy Of Report
Histone Deacetylase Inhibitors Market 2020 Growth Projection by Leading Players: …
Global Histone Deacetylase Inhibitors Market Size, Share and Global Trend By Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Geography Forecast till 2026. To know How COVID-19 Pandemic Will Impact This Market/Industry -Request a sample copy of the report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/histone-deacetylase-inhibitors-market-100323 Histone Deacetylase Inhibitors Market Key Companies Analyzed: Abcam plc., Cetya Therapeutics, RandD Systems, Inc., Mirati